Inflammatory Bowel Disease Drugs Market Size Worth USD 34.5 Billion, Globally, by 2031 at 5.1% CAGR: AMR
Allied Market Research has published a study report with the title Inflammatory Bowel Disease Drugs Market Size was Valued at USD 21.0 billion in 2021 and is Anticipated to Garner USD 34.5 billion by 2031, registering a CAGR of 5.1% from 2022 to 2031. The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and evolving market trends. The market study is a helpful source of information for the frontrunners, new entrants, investors, and shareholders in crafting strategies for the future and heightening their position in the market.
๐๐ก๐๐ญ ๐๐ซ๐ ๐ญ๐ก๐ ๐๐๐๐ญ๐จ๐ซ๐ฌ ๐๐ซ๐ข๐ฏ๐ข๐ง๐ ๐ญ๐ก๐ ๐ข๐ง๐๐ฅ๐๐ฆ๐ฆ๐๐ญ๐จ๐ซ๐ฒ ๐๐จ๐ฐ๐๐ฅ ๐๐ข๐ฌ๐๐๐ฌ๐ ๐ญ๐ซ๐๐๐ญ๐ฆ๐๐ง๐ญ ๐ฆ๐๐ซ๐ค๐๐ญ?
Rise in prevalence of ulcerative colitis and Crohnโs disease, growing awareness of the disease across the world, increase in development of new drugs, increased government support for the management of inflammatory bowel disease drives the growth of the global inflammatory bowel disease treatment market. Based on type, the Crohnโs disease segment is likely to maintain its dominance through 2031. Region wise, Asia-Pacific would exhibit the fastest CAGR during the forecast period.
Get Sample PDF Report with Graphs and Figures Here: https://www.alliedmarketresearch.com/request-sample/4318
Covid-19 Scenario:
- The COVID-19 pandemic had a positive impact on the growth of the inflammatory bowel disease treatment market. This is due to the increase in number of government initiatives to protect patients with inflammatory bowel disease, as those patients were more prone to acquire infection due to their immunosuppressive therapies.
- The pharmaceutical sector opened new approaches and collaborations in the industry to respond to the urgent needs of the pandemic.
- The market is anticipated to grow even more in the post-pandemic.
๐๐จ๐ฉ ๐๐ง๐๐ฅ๐๐ฆ๐ฆ๐๐ญ๐จ๐ซ๐ฒ ๐๐จ๐ฐ๐๐ฅ ๐๐ข๐ฌ๐๐๐ฌ๐ ๐๐ซ๐ฎ๐ ๐ฌ ๐๐จ๐ฆ๐ฉ๐๐ง๐ข๐๐ฌ
- AbbVie Inc.
- Bristol Myers Squibb
- Celltrion Healthcare
- Eli-Lilly
- Johnson & Johnson Services Inc.
- Merck & Co, Inc.
- Novartis AG
- Pfizer Inc.
- Takeda Pharmaceutical Company Ltd.
- UCB S.A.
๐๐ง๐๐ฅ๐๐ฆ๐ฆ๐๐ญ๐จ๐ซ๐ฒ ๐๐จ๐ฐ๐๐ฅ ๐๐ข๐ฌ๐๐๐ฌ๐ ๐๐ซ๐ฎ๐ ๐ฌ ๐๐๐ซ๐ค๐๐ญ ๐ฌ๐๐ ๐ฆ๐๐ง๐ญ๐๐ญ๐ข๐จ๐ง ๐๐๐ง ๐๐ ๐๐จ๐ง๐ ๐๐๐ฌ๐๐ ๐จ๐ง ๐ฌ๐๐ฏ๐๐ซ๐๐ฅ ๐๐๐๐ญ๐จ๐ซ๐ฌ, ๐ข๐ง๐๐ฅ๐ฎ๐๐ข๐ง๐ :
The report offers a detailed segmentation of the global inflammatory bowel disease treatment market based on type, drug class, distribution channel, and region. The report provides an analysis of each segment and sub-segment with the help of tables and figures. This analysis helps market players, investors and new entrants in determining the sub-segments to be tapped on to achieve growth in the coming years.
Based on type, the Crohnโs disease segment was the largest market in 2021, contributing to more than two-thirds of the global inflammatory bowel disease treatment market, and is likely to maintain its leadership status during the forecast period. However, the ulcerative colitis segment is expected to manifest the highest CAGR of 6.9% from 2022 to 2031.
Based on drug class, the TNF inhibitors segment held the largest share in 2021, accounting for nearly half of the global inflammatory bowel disease treatment market, and would rule the roost through 2031. However, the JAK inhibitors segment is estimated to witness the fastest CAGR of 12.4% during the forecast period. The research also encompasses a study of the segments such as corticosteroids, aminosalicylates, anti-integrin, IL inhibitors and others.
Based on distribution channel, the drug store and retail pharmacy segment was largest market in 2021, accounting for nearly three-fifths of the global inflammatory bowel disease treatment market, and is likely to maintain its leadership status during the forecast period. However, the online pharmacy segment is expected to manifest the highest CAGR of 7.1% from 2022 to 2031. The research also analyzes the hospital pharmacy segment.
Based on region, North America accounted for the largest share in 2021, contributing to more than two-fifths of the global inflammatory bowel disease treatment market, and is likely to dominate the market during the forecasted timeframe. However, Asia-Pacific is expected to exhibit the fastest CAGR of 6.6% during the forecast period. The research also analyzes the regions including Europe and LAMEA.
Purchase the Report: https://www.alliedmarketresearch.com/purchase-enquiry/4318
Our Market Research Solution Provides You Answer to Below Mentioned Question:
- Which are the driving factors responsible for the growth of market?
- Which are the roadblock factors of this market?
- What are the new opportunities, by which market will grow in coming years?
- What are the trends of this market?
- Which are main factors responsible for new product launch?
- How big is the global & regional market in terms of revenue, sales and production?
- How far will the market grow in forecast period in terms of revenue, sales and production?
- Which region is dominating the global market and what are the market shares of each region in the overall market in 2022?
- How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?
- Which region has more opportunities?
By Region Outlook
- North America
(U.S., Canada, Mexico) - Europe
(Germany, France, UK, Italy, Spain, Rest of Europe) - Asia-Pacific
(Japan, China, India, Rest of Asia-Pacific) - LAMEA
(Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Contact Details:
David Correa
USA/Canada (Toll-Free): +1-800-792-5285, +1-503-894-6022
help@alliedmarketresearch.com
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of โMarket Research Reportsโ and โBusiness Intelligence Solutions.โ AMR has a targeted view to provide business insights and consulting to assist its clients in making strategic business decisions and achieve sustainable growth in their respective market domain.
Editor Details
-
Company:
- The Wire Times